Small-Molecule E6 Binders for Therapeutic HPV Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HPV vaccines are ineffective for treating established HPV infections and associated cancers, and existing treatments carry significant morbidity and financial burden, while HPV E6 protein is crucial for viral replication and epithelial cell transformation.

Innovation Solution

Development of small molecule compounds that covalently bind to the HPV E6 protein, disrupting its interaction with E6AP and restoring wild-type p53 protein levels and function, thereby inhibiting HPV replication and tumor progression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HPV vaccines are used for prophylaxis, then prevention of HPV infection is effective, but treatment of established HPV infections and cancers is not achieved

Engineering Contradiction:

Improveprevention effectivenessVSAvoidtherapeutic applicability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention segments the protective function into two distinct components: prophylactic vaccination for uninfected individuals and therapeutic intervention for infected individuals. The therapeutic component uses small molecule compounds that specifically target and neutralize the E6 protein in already-infected cells, allowing the system to address both prevention and treatment needs through different mechanisms.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention introduces small molecule compounds as intermediary agents that bridge the gap between vaccine protection and cancer treatment. These compounds act as therapeutic mediators by binding to the E6 protein and disrupting its interaction with p53, providing a therapeutic mechanism that complements the prophylactic vaccine approach.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If destructive surgical remedies are used for HPV-related lesions, then removal of pre-malignant and malignant tissues is effective, but patient morbidity and financial burden increase significantly

Engineering Contradiction:

Improvelesion removal effectivenessVSAvoidpatient morbidity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention replaces mechanical surgical removal with a biochemical mechanism. Small molecule compounds are administered that specifically bind to and neutralize the E6 oncoprotein within infected cells, triggering apoptosis or differentiation of pre-malignant cells without the need for physical excision, thereby eliminating tissue damage and surgical complications.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The small molecule compounds serve as intermediary agents that mediate the destruction of HPV-infected cells through biochemical pathways rather than mechanical force. These compounds act as therapeutic mediators that restore p53 function and induce cell death in malignant cells while sparing healthy tissue, providing a selective and less harmful alternative to surgery.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If HPV E6 protein functions are maintained, then viral replication and epithelial cell transformation proceed, but small molecule compounds can covalently bind to E6 to disrupt these functions

Engineering Contradiction:

Improveviral replication efficiencyVSAvoidtherapeutic inhibition effectiveness

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention extracts the E6 protein's harmful functions by introducing small molecule compounds that bind covalently to the E6 protein. This extraction of function prevents E6 from interacting with p53 and other cellular targets, thereby halting viral replication and cell transformation processes while allowing the viral protein structure to remain intact.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention converts the E6 protein's essential role in viral pathogenesis into a therapeutic target. By designing small molecule compounds that specifically recognize and bind to the E6 protein's functional domains, the harmful activity of E6 is transformed into a beneficial therapeutic effect, where the protein's own structure facilitates its neutralization by the drug compounds.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively block HPV E6 functions, potentially eliminating HPV DNA from pre-malignant tissues and treating HPV-induced cancers, both topically and systemically.

Implementation Method 1

small molecule compounds that covalently bind to the HPV E6 protein

Methodology Applied

Scientific EffectCovalent binding: Chemical Bonding

Data Source

PatentUS12533339B2Small molecule antiviral drug treatment for human papillomavirus infections

Publication Date: 2026.01.27 THE TRUSTEES OF INDIANA UNIV

AI summary

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.